Boehringer Ingelheim (BI), the maker of Pradaxa, is accused of intentionally misusing their medical-professional-only website. An anonymous general practitioner has accused the company of intending to market Pradaxa to the general public through their site that is supposedly intended only for medical professionals.
The Prescription Medicines Code of Practice Authority (PMCPA) is the British organization responsible for monitoring the promotion of prescription medicines to health professionals and the provision of information to the public about prescription-only medicines.
Although the PMCPA did not find that BI’s medical professionals website was being used to target the public, it did cite BI for not providing a clear, prominent statement as to where the prescribing information can be found. This was a direct violation of clause 4.6 of the Code of Practice.
On a much larger scale, Pradaxa is under scrutiny for large numbers of reported hemorrhages among those using the medication. In response to the alarming number of adverse events, the number of lawsuits against Boehringer Ingelheim continues to rise.